New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - ustekinumab 90mg;   - solution for injection - 90 mg - active: ustekinumab 90mg   excipient: histidine as histidine hydrochloride polysorbate 80 sucrose water for injection - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

United Kingdom - English - myHealthbox

janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 36 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (adhd) in children aged 6 years of age and over when remedial measures alone prove insufficient

United Kingdom - English - myHealthbox

janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 18 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (adhd) in children aged 6 years of age and over when remedial measures alone prove insufficient.

United Kingdom - English - myHealthbox

janssen-cilag ltd - methylphenidate hydrochloride - prolonged-release tablet - 54 mg - centrally acting sympathomimetics - it is indicated as part of a comprehensive treatment programme for attention deficit hyperactivity disorder in children aged 6 years of age and over when remedial measures alone prove insufficient.

United Kingdom - English - myHealthbox

janssen-cilag ltd - norgestimate, ethinylestradiol - film-coated tablet - 35/ 250 micrograms - hormonal contraceptives for systemic use; progestogens and estrogens, fixed combinations - contraception and the recognised indications for such estrogen/progestogen combinations

United Kingdom - English - myHealthbox

janssen-cilag ltd - fentanyl - transdermal patch - 2.1 mg - phenylpiperidine derivatives - in adults: is indicated in the management of chronic intractable pain due to cancer; in the management of chronic intractable pain in children:is indicated in long term management of severe chronic pain in children receiving opioid therapy from 2 years of age.

United Kingdom - English - myHealthbox

janssen-cilag ltd - fentanyl - transdermal patch - 16.8 mg. - opioid analgesic, phenylpiperidone derivative - in adults it is indicated in the management of chronic intractable pain due to cancer and in the management of chronic intractable pain in children it is indicated for long term management of severe chronic pain in children receiving opioid therapy from 2 years of age

United Kingdom - English - myHealthbox

janssen-cilag ltd - risperidone - tablets - 4 mg - other antipsychotic - it is indicated for the treatment of schizophrenia; for the treatment of moderate to severe manic episodes associated with bipolar disorders; in patients with moderate to severe alzheimer's dementia; forf persistent aggression in conduct disorder in children from the age of 5 years and adolescents with subaverage intellectual functioning or mental retardation

United Kingdom - English - myHealthbox

janssen-cilag ltd - risperidone - tablets - 3 mg - other antipsychotic - it al is used to treat the following: schizophrenia, mania, aggression in people with alzheimer’s dementia, aggression in intellectually disabled children (at least 5 years of age) and adolescents with conduct disorder.

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - canagliflozin hemihydrate 102mg equivalent to canagliflozin 100 mg - film coated tablet - 100 mg - active: canagliflozin hemihydrate 102mg equivalent to canagliflozin 100 mg excipient: croscarmellose sodium hyprolose lactose magnesium stearate microcrystalline cellulose opadry ii yellow 85f92209 - invokana is indicated in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise, to improve glycaemic control as: monotherapy: when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. add-on combination therapy: combination therapy with other anti-hyperglycaemic agents including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.